The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - A population-based study

Leukemia and Lymphoma

Volumn 48, Issue 4, 2007, Pages 736-745

  Hasselblom, Sverker ^a   Ridell, Börje ^a   Nilsson Ehle, Herman ^a   Andersson, Per Ola ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diffuse large B cell lymphoma; Gender; IPI; Population based; Prognostic factors

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; AGING; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CLINICAL ASSESSMENT; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SURVIVAL RATE; SWEDEN; TREATMENT RESPONSE;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 34247186903     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601187703     Document Type: Article

References (26)

1. McKelvey, E. M., Gottlieb, J. A., Wilson, H. E., Haut, A., Talley, R. W. and Stephens, R. (1976) Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer, 38, pp. 1484-1493.
2. Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H. and Bouabdallah, R. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346, pp. 235-242.
3. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A. C. and Rube, C. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood, 104, pp. 634-641.
4. Krol, A. D., Cessie, S le, Snijder, S., Kluin-Nelemans, J. C., Kluin, P. M. and Noordijk, E. M. (2003) Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. Leuk Lymphoma, 44, pp. 451-458.
5. Moller, M. B., Pedersen, N. T. and Christensen, B. E. (2004) Diffuse large B-cell lymphoma: Clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol, 124, pp. 151-159.
6. Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K. and Klasa, R. (2005) Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 23, pp. 5027-5033.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med, 329, pp. 987-994.
8. Hermans, J., Krol, A. D., van Groningen, K., Kluin, P. M., Kluin-Nelemans, J. C. and Kramer, M. H. (1995) International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood, 86, pp. 1460-1463.
9. Janssen-Heijnen, M. L., van Spronsen, D. J., Lemmens, V. E., Houterman, S., Verheij, K. D. and Coebergh, J. W. (2005) A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of International Prognostic Index. Br J Haematol, 129, pp. 597-606.
10. World Health Organization Classification of Tumours (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon
11. Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P. and Young, R. C. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol, 7, pp. 1630-1636.
12. Hryniuk, W. M. and Goodyear, M. (1990) The calculation of received dose intensity. J Clin Oncol, 8, pp. 1935-1937.
13. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, pp. 1244-1253.
14. Schemper, M. and Smith, T. L. (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials, 17, pp. 343-346.
15. Maartense, E., Hermans, J., Kluin-Nelemans, J. C., Kluin, P. M., Van Deijk, W. A. and Snijder, S. (1998) Elderly patients with non-Hodgkin's lymphoma: Population-based results in The Netherlands. Ann Oncol, 9, pp. 1219-1227.
16. Vose, J. M., Armitage, J. O., Weisenburger, D. D., Bierman, P. J., Sorensen, S. and Hutchins, M. (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol, 6, pp. 1838-1844.
17. Coiffier, B., Gisselbrecht, C., Vose, J. M., Tilly, H., Herbrecht, R. and Bosly, A. (1991) Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol, 9, pp. 211-219.
18. Grogan, L., Corbally, N., Dervan, P. A., Byrne, A. and Carney, D. N. (1994) Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens. Ann Oncol, 5, pp. 47-51.
19. Zinzani, P. L., Storti, S., Zaccaria, A., Moretti, L., Magagnoli, M. and Pavone, E. (1999) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood, 94, pp. 33-38.
20. Osby, E., Hagberg, H., Kvaloy, S., Teerenhovi, L., Anderson, H. and Cavallin-Stahl, E. (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: Results of a Nordic Lymphoma Group randomized trial. Blood, 101, pp. 3840-3848.
21. Bairey, O., Benjamini, O., Blickstein, D., Elis, A. and Ruchlemer, R. (2006) Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol, 17, pp. 928-934.
22. Moller, M. B., Christensen, B. E. and Pedersen, N. T. (2003) Prognosis of localized diffuse large B-cell lymphoma in younger patients. Cancer, 98, pp. 516-521.
23. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339, pp. 1506-1514.
24. Federico, M., Vitolo, U., Zinzani, P. L., Chisesi, T., Clo, V. and Bellesi, G. (2000) Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood, 95, pp. 783-789.
25. Catovsky, D., Fooks, J. and Richards, S. (1989) Prognostic factors in chronic lymphocytic leukaemia: The importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol, 72, pp. 141-149.
26. Osby, E., Askling, J., Landgren, O., Dickman, P. W., Ekbom, A. and Bjorkholm, M. (2004) Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma. Acta Oncol, 43, pp. 297-301.